ClinicalTrials.gg
RecruitingNCT04130659GENYAL®Updated Dec 15, 2023

Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone

An interventional study of MARIAL® + PPI (generic Omeprazole) and PPI alone (generic omeprazole) in Gastroesophageal Reflux Disease (GERD), sponsored by Nekkar Lab Srl. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Nekkar Lab Srl · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing Proton pump inhibitors (PPIs) in Gastroesophageal Reflux — 7 open to participants now, 7 under way, none of them phase 3. A drug class: Proton pump inhibitors (PPIs) · Gastroesophageal Reflux.

Planned enrollment
87th of 212
110 · median 78
Started
2019
the only one that year
No phase
34 of 214
5 open now
Registered
194th of 214
by date

Among the 214 studies testing Proton pump inhibitors (PPIs) in Gastroesophageal Reflux, this one is the 87th largest by planned enrollment of the 212 interventional ones that give a count, is the only one that started in 2019, is one of 34 with no phase, and was the 194th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

7 of the 214 studies testing Proton pump inhibitors (PPIs) in Gastroesophageal Reflux are open now, in 8 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Proton pump inhibitors (PPIs)

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing Proton pump inhibitors (PPIs) in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

Many patients with acid reflux disease do not improve with regular doses of proton pump inhibitors (e.g., omeprazole). The goals of this clinical trial is the to see if taking MARIAL®, in combination with omeprazole, for one month improves symptoms of acid reflux disease compared to taking omeprazole alone.

Furthermore, this study will verify the effectiveness of MARIAL® as a maintenance treatment for the next five months.

This trial is called by the registered name GENYAL®.

Read the detailed description

This is an open-label, comparative, multicenter study with two parallel groups of patients. The clinical trial has the registered name GENYAL® and will be conducted at five clinical sites.

The study population will include patients affected by gastroesophageal reflux disease (GERD) with a diagnosis of Los Angeles Classification System Grade A reflux esophagitis confirmed by gastroscopy (performed within 1 month prior to baseline) and clinical symptoms in the past 2 weeks.

Patients will be randomized to receive MARIAL® (E-Gastryal®+Magnesium Alginate) plus omeprazole versus omeprazole alone (1 month) followed by Marial® alone for an additional 5 months. The products will be administered following the respective Summary of Product Characteristics. The Investigators chosen the number of rescue medicine used (tablets of Gaviscon®) as a primary efficacy outcome to measure the performance between the two groups. The study will enroll 110 patients.

MARIAL® is a class IIa medical device that is already marketed in several EU countries. It is a combination of E-Gastryal® (hyaluronic acid, hydrolyzed keratin, tara gum, xantan gum, purified water) and magnesium alginate (MgAlg). It has been proven to actively regenerate damaged tissues through its repair and regenerative properties on the mucous membranes and its mucoadhesive and film-forming properties, which prolong the contact time with the mucous membranes and consequently improve their effectiveness.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • Medical Device
  • Proton-pump inhibitor
  • Gastroesophageal Reflux Disease
  • Magnesium Alginate
  • Mucosal protective agent
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant female, both aged ≥ 18 to ≤ 65 years.
  • Diagnosis of GERD Grade A esophagitis on Los Angeles Classification System grades reflux esophagitis by:

    • gastroscopy (done within 1-month prior baseline).
    • episodic heartburn and/or acid regurgitation (at least 3 times per week in the last 2 weeks);
  • of ≥ 18.5 to ≤ 36 kg/m2.
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.
  • Capable of and freely willing to provide written prior to participating in the study.

Exclusion criteria

Exclusion Criteria:

  • Intake of PPI or Marial® during the last 28 days before the start of the study.
  • Intake of systemic or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (≥ 3 consecutive days per week) during the last 28 days before the start of the study; except regular intake of enteric coated aspirin dosages up to 150 mg/d.
  • Previously underwent acid-lowering surgery or other surgery of the oesophagus and/or upper gastrointestinal tract (excluding appendectomy, cholecystectomy and polypectomy).
  • History of co-existing disease that affects the esophagus (e.g. Barrett's esophagus, Zollinger-Ellison syndrome, esophageal stricture).
  • History of active gastric or duodenal ulcers within 3 months of the first dose of the study drug or had acute upper gastrointestinal (GI) bleeding within last 6 months.
  • Documented presence of severe renal or hepatic insufficiency (i.e. GOT, GPT elevated over double the normal range).
  • Known to omeprazole, and/or Marial® and/or Gaviscon®.
  • Concurrent (or within 30 days of study entry) participation in a clinical trial.
  • Females who are pregnant, or planning a pregnancy, or lactating. Females of child bearing potential not using reliable methods of .
  • laboratory abnormality or disease which, in the opinion of the Investigator, will create a risk for the patient, or interfere with study results (i.e. GOT, GPT elevated over double the normal range).
  • Receiving any of the following drugs within 2 weeks before the baseline: theophylline, bismuth salts, warfarin, phenytoin, tacrolimus, diazepam, cyclosporine, disulfiram, barbiturates, antineoplastic agents, erythromycin, clarithromycin, sucralfate, clopidogrel or protease inhibitors. Benzodiazepines could be allowed only in concomitance with the endoscopy.
  • Taking concomitant medications that rely on the presence of gastric acid for optimal bioavailability (e.g. ketoconazole, ampicillin esters or iron salts).
  • Drug or alcohol abuse within 12 months of Day 0
  • (also leukemic infiltrates) within 5 years prior to Day 0 (except for treated basal cell/squamous cell carcinoma of the skin).
  • Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or suicidal ideation, or any other psychiatric illness (except for intermittent anxiety).
  • Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study for its safety
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    MARIAL® and PPI; Follow-up period: MARIAL® alone

    Period 1, open comparative phase: MARIAL® and PPI administered from day 1 to day 28. Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6.

    Combination Product: MARIAL® + PPI (generic Omeprazole) · Device: MARIAL® alone

  • Active comparator
    PPI alone; Follow-up period: MARIAL® alone

    Period 1, open comparative phase: PPI alone administered from day 1 to day 28. Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6.

    Drug: PPI alone (generic omeprazole) · Device: MARIAL® alone

Interventions

  • Combination productMARIAL® + PPI (generic Omeprazole)

    Drug page: Proton pump inhibitors (PPIs)

    MARIAL® administration: 1 stick twice daily after meals from day 1 to 28. Omeprazole administration: 20 mg cps once daily from day 1 to day 28

  • Omeprazole administration: 20 mg cps once daily from day 1 to day 28

  • DeviceMARIAL® alone

    MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.

06

What researchers measure

Primary outcomes

  1. Total Gaviscon® tablets consumption by patients using alginate as rescue medication

    The 28-day visit will assess the outcome by reviewing the patients' diary card. This diary card records their usage of Gaviscon® tablets and calculates the number of unused Gaviscon® tablets they received during baseline. The consumption of Gaviscon® tablets from baseline to the final visit in the Marial® + PPI group will be compared to that of the PPI-only group.

    Time frame: 28 days

Secondary outcomes

  1. Reflux Symptoms Index (RSI)

    RSI is a nine-item self-administered outcome instrument with a maximum total score of 45. The total score can range from zero to 45, with each item being measured using a 6-point rating scale from no problem (0) to severe problem (5). If the score is greater than 13, the RSI will be clinically significant and indicative of reflux disease.

    Time frame: 180 days

  2. GERD Impact Scale (GIS)

    The GERD Impact Scale (GIS) consists of nine questions that cover acid-related symptoms, chest pain, extra-esophageal symptoms, and how the symptoms affect a patient's daily life, including sleep, work, meals, social occasions, and use of over-the-counter medications. The patient will provide their responses using the following four-point Likert scale; 1=none of the time, 2=a little of the time, 3=some of the time, and 4=all of the time for the seven days leading up to the study visit.

    Time frame: 180 days

  3. GERD Health-Related Quality of Life (GERD-HRQL)

    This study employs the 10-item version of the GERD-HRQL questionnaire (Velanovich, V. Diseases of the Esophagus, 2007), which measures intensity and frequency of heartburn, difficulty in swallowing, bloating, and burden of GERD medications. . Responses are rated on a scale of 1 to 5. 0 = No symptoms, 1 = Noticeable but not bothersome, 2 = Noticeable and bothersome but not occurring every day, 3 = Bothersome on a daily basis, 4 = Bothersome and affecting daily activities, 5 = Incapacitating in terms of daily activities. An additional patient-reported global satisfaction score is not added to the total GERD-HRQL score. Hence, the maximum score for this test is 50 and higher scores indicate more severe symptoms and a reduced health-related quality of life.

    Time frame: 180 days

  4. Investigator Global Assessment of the Performance (IGAP)

    Investigator Global Assessment of the Performance (IGAP) will be scored by Investigator as: 1= very good performance, 2 = good performance, 3 = moderate performance and 4 = poor performance. IGAP will be evaluated at day 28 and day 180, only.

    Time frame: 180 days

  5. Investigator Global Assessment of Safety (IGAS)

    Investigator Global Assessment of Safety (IGAS) will be measured using the following 4-point verbal rating scale:1= very good safety, 2 = good safety, 3 = moderate safety and 4 = poor safety. IGAP will be evaluated at day 28 and day 180, only.

    Time frame: 180 days

  6. Serious Adverse Device Effects (SADE), Serious Adverse Events (SAE), Adverse Device Effects (ADE), Adverse Events (AE), and Device Deficiency (DD)

    Serious Adverse Device Effects (SADE), Serious Adverse Events (SAE), Adverse Device Effects (ADE), Adverse Events (AE), and Device Deficiency (DD) will be collected and reported by the investigators during the study period. Their incidence will be assessed based on the change from the baseline.

    Time frame: 180 days

  7. Esophagogastroduodenoscopy (EGD)

    Esophagogastroduodenoscopy (EGD) will be evaluated as exploratory outcome. It is a minimally invasive diagnostic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Prior to the procedure, benzodiazepine will be administered for sedation. EGD will be performed at baseline and on day 28 for the 16 patients included in the Italian site only.

    Time frame: 28 days

  8. GERD recurrence rate

    GERD recurrence rate will be evaluated as an exploratory outcome. The rate of GERD recurrence will be assessed by comparing the change from day 28 to day 180.

    Time frame: 150 days

07

Study locations

1 of 5 sites recruiting
  • UOC Endoscopia Digestiva Chirurgica Policlinico Gemelli - Universita Cattolica
    Roma, 00168, Italy
    Recruiting
  • Cabinet Particular Policlinic Algomed
    Timișoara, Timis 300002, Romania
    Completed

    Not enrolling at this site.

  • Societatea Civilă Medicală Gados
    Timişoara, 300209, Romania
    Completed

    Not enrolling at this site.

  • Medlife SA
    Timişoara, 300551, Romania
    Completed

    Not enrolling at this site.

  • Centrul Medical Salvosan Ciobanca
    Zalău, 45051, Romania
    Completed

    Not enrolling at this site.

08

References and documents

Publications

  • El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13. PubMed 23853213 ↗
  • Kung YM, Hsu WH, Wu MC, Wang JW, Liu CJ, Su YC, Kuo CH, Kuo FC, Wu DC, Wang YK. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci. 2017 Dec;62(12):3298-3316. doi: 10.1007/s10620-017-4830-5. Epub 2017 Nov 6. PubMed 29110162 ↗
  • Strugala V, Avis J, Jolliffe IG, Johnstone LM, Dettmar PW. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol. 2009 Aug;61(8):1021-8. doi: 10.1211/jpp/61.08.0005. PubMed 19703345 ↗
  • Aragona SE, Mereghetti G, Bianchetti M, Mangiavillano B, Zurlo T, Lotti J, La Mantia I, Franca K, Lotti T. Regenerative medicine in the treatment of gastro-esophageal reflux disease and laryngo-pharyngeal reflux. From research to cure. J Biol Regul Homeost Agents. 2017 APR-JUN;31(2 Suppl. 2):207-212. PubMed 28702984 ↗
  • DeVault K, McMahon BP, Celebi A, Costamagna G, Marchese M, Clarke JO, Hejazi RA, McCallum RW, Savarino V, Zentilin P, Savarino E, Thomson M, Souza RF, Donohoe CL, O'Farrell NJ, Reynolds JV. Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. Ann N Y Acad Sci. 2013 Oct;1300:278-295. doi: 10.1111/nyas.12253. PubMed 24117649 ↗
  • Aragona SE, Mereghetti G, Ciprandi G. Gastric reflux: the therapeutical role of Marial(R). J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):969-972. PubMed 29687692 ↗
  • Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017 Sep 1;30(9):1-15. doi: 10.1093/dote/dox055. PubMed 28859358 ↗
  • Reimer C, Lodrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016 Apr;43(8):899-909. doi: 10.1111/apt.13567. Epub 2016 Feb 22. PubMed 26909885 ↗
  • Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002 Jun;16(2):274-7. doi: 10.1016/s0892-1997(02)00097-8. PubMed 12150380 ↗
  • Jones R, Coyne K, Wiklund I. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther. 2007 Jun 15;25(12):1451-9. doi: 10.1111/j.1365-2036.2007.03343.x. PubMed 17539985 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Dec 2024, 64 months after the start.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 64 months is above that.

Counting every sponsor, half of 227 studies reached it within 31 months; a quarter within 12 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 17, 2019
StartActual
Aug 8, 2019
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jan 31, 2025
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04130659
Lead sponsor
Nekkar Lab Srl
Collaborators
Opera CRO, a TIGERMED Group Company
Responsible party
Sponsor
First posted
Oct 17, 2019
Start date
Aug 8, 2019
Primary completion
Dec 31, 2024 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Dec 15, 2023

Study contacts

Barattini Dionisio Franco
Contact
barattini@operacro.com
+39 3355437574
Dogaru Dumitru-Emanuel
Contact
dogaru@operacro.com
+40 724345115
Doina Rosu
principal investigator · Societatea Civilă Medicală Gados

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Proton pump inhibitors (PPIs)

Start the discussion